Kineret (anakinra subcutaneous injection) — Cigna
Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
Initial criteria
- Genetic testing has confirmed bi-allelic pathogenic variants in the IL1RN gene; AND
- The medication is prescribed by or in consultation with a rheumatologist, geneticist, dermatologist, or a physician specializing in the treatment of autoinflammatory disorders
Reauthorization criteria
- Patient has been established on this medication for at least 6 months
Approval duration
initial 6 months; reauth 1 year